Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 288

1.

Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Silver H, Chertkow Y, Weinreb O, Danovich L, Youdim M.

Neurotherapeutics. 2009 Jan;6(1):86-93. doi: 10.1016/j.nurt.2008.10.034. Review.

PMID:
19110201
[PubMed - indexed for MEDLINE]
2.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
[PubMed - indexed for MEDLINE]
3.

Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

Silver H.

Expert Opin Pharmacother. 2004 Oct;5(10):2053-8. Review.

PMID:
15461540
[PubMed - indexed for MEDLINE]
4.

The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions.

Silver H, Einoch R, Youdim M, Weinreb O.

Curr Med Chem. 2013;20(3):363-70. Review.

PMID:
23157628
[PubMed - indexed for MEDLINE]
5.

Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Chertkow Y, Weinreb O, Youdim MB, Silver H.

J Neural Transm. 2009 Nov;116(11):1529-41. doi: 10.1007/s00702-009-0255-4. Epub 2009 Jul 4. Review.

PMID:
19578925
[PubMed - indexed for MEDLINE]
6.

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

Silver H.

Int Clin Psychopharmacol. 2003 Nov;18(6):305-13. Review.

PMID:
14571150
[PubMed - indexed for MEDLINE]
7.

The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment.

Danovich L, Weinreb O, Youdim MB, Silver H.

Int J Neuropsychopharmacol. 2011 Mar;14(2):143-55. doi: 10.1017/S1461145710000106. Epub 2010 Feb 25.

PMID:
20181299
[PubMed - indexed for MEDLINE]
8.

SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients.

Silver H, Susser E, Danovich L, Bilker W, Youdim M, Goldin V, Weinreb O.

Int J Neuropsychopharmacol. 2011 Jun;14(5):573-84. doi: 10.1017/S1461145710001471. Epub 2010 Dec 16.

PMID:
21208484
[PubMed - indexed for MEDLINE]
9.

Fluvoxamine as an adjunctive agent in schizophrenia.

Silver H.

CNS Drug Rev. 2001 Fall;7(3):283-304. Review.

PMID:
11607044
[PubMed - indexed for MEDLINE]
10.

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.

Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32. doi: 10.1016/j.euroneuro.2009.04.003. Epub 2009 May 2.

PMID:
19411165
[PubMed - indexed for MEDLINE]
11.

Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis.

Sepehry AA, Potvin S, Elie R, Stip E.

J Clin Psychiatry. 2007 Apr;68(4):604-10.

PMID:
17474817
[PubMed - indexed for MEDLINE]
12.

[The place of SSRIs in the treatment of schizophrenia].

Zullino D, Delacrausaz P, Baumann P.

Encephale. 2002 Sep-Oct;28(5 Pt 1):433-8. Review. French.

PMID:
12386545
[PubMed - indexed for MEDLINE]
13.
14.

Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex.

Danovich L, Weinreb O, Youdim MB, Silver H.

Psychopharmacology (Berl). 2012 Apr;220(4):763-70. doi: 10.1007/s00213-011-2530-y. Epub 2011 Oct 12.

PMID:
21989809
[PubMed - indexed for MEDLINE]
15.

[Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].

Weimer E, Braus DF, Cavus I, Thome J.

Fortschr Neurol Psychiatr. 2002 Apr;70(4):210-7. Review. German.

PMID:
11948436
[PubMed - indexed for MEDLINE]
16.

Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs.

DeBattista C, Sofuoglu M, Schatzberg AF.

Biol Psychiatry. 1998 Sep 1;44(5):341-7.

PMID:
9755356
[PubMed - indexed for MEDLINE]
17.

A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.

Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ.

J Clin Psychiatry. 2009 Jun;70(6):863-8. doi: 10.4088/JCP.08m04369. Epub 2009 May 5.

PMID:
19422759
[PubMed - indexed for MEDLINE]
18.

The use of antidepressants in novel combination therapies.

Shelton RC.

J Clin Psychiatry. 2003;64 Suppl 2:14-8. Review.

PMID:
12625794
[PubMed - indexed for MEDLINE]
19.

Serotonergic approaches in the development of novel antipsychotics.

Jones CA, McCreary AC.

Neuropharmacology. 2008 Nov;55(6):1056-65. doi: 10.1016/j.neuropharm.2008.05.025. Epub 2008 Jun 3. Review.

PMID:
18621404
[PubMed - indexed for MEDLINE]
20.

Augmentation strategies for treatment-resistant depression.

Carvalho AF, Machado JR, Cavalcante JL.

Curr Opin Psychiatry. 2009 Jan;22(1):7-12. doi: 10.1097/YCO.0b013e32831be9ef. Review.

PMID:
19122528
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk